United States


DRRX.OQ on NASDAQ Stock Exchange Global Market

21 Apr 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Durect presents data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)
8:00am EDT 

April 24 (Reuters) - Durect Corp :Durect announces presentation of data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH).DUR-928 was well tolerated in study.Additional studies, including larger controlled trials, will be required to confirm findings.Durect - reduction of biomarkers, results from animal, cell culture studies suggest potential therapeutic activity of DUR-928 in patients with liver disease.  Full Article

Durect Corporation posts Q4 loss per share $0.06
Tuesday, 14 Mar 2017 04:02pm EDT 

Durect Corp : Durect Corporation announces fourth quarter and full year 2016 financial results and update of programs . Q4 revenue $3.5 million versus I/B/E/S view $3.6 million .Qtrly loss per share $0.06.  Full Article

Durect Corp qtrly loss per share $0.07
Monday, 1 Aug 2016 04:05pm EDT 

Durect Corp : Durect corporation announces second quarter 2016 financial results and update of programs . Q2 revenue $3.2 million versus i/b/e/s view $3.7 million . Qtrly loss per share $0.07 .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Durect says PDUFA date for remoxy NDA of Sept 25 unchanged
Friday, 1 Jul 2016 09:05am EDT 

Durect Corp : Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged . An FDA advisory committee meeting for remoxy is not needed and no change to September 25, 2016 PDUFA date . Pain Therapeutics stated that FDA advised them that regulatory review of remoxy new drug application (NDA) remains active and on-going .Durect provides remoxy update.  Full Article

DURECT Corp announces pricing of public offering of common stock
Tuesday, 26 Apr 2016 09:00am EDT 

DURECT Corp:Pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public.Gross proceeds to DURECT from this offering are expected to be $15 million.Offering is expected to close on or about April 29.  Full Article

DURECT Corp announces positive Phase 1 Data for DUR-928
Wednesday, 6 Jan 2016 08:00am EST 

DURECT Corp:Announces positive Phase 1 Data for DUR-928.Says DURECT is now positioned to commence patient trials in 2016 with DUR-928.DUR-928 was well-tolerated at all dose levels, with no treatment-related adverse events reported and plasma levels were dose proportional.  Full Article

DURECT announces plans for new Posidur (saber®-bupivacaine) clinical trial
Tuesday, 23 Jun 2015 08:00am EDT 

DURECT Corp:Announces plans for a new Posidur(TM) (saber®-bupivacaine) clinical trial.Anticipates beginning the trial in the fall of 2015 and expects that it will take approximately one year to complete enrollment.Plans to conduct a new posidur phase 3 clinical trial consisting of about 300 patients undergoing laparoscopic cholecystectomy surgery.  Full Article

DURECT announces positive results from DUR-928 Multi-Dose Phase 1 Study
Monday, 18 May 2015 08:30am EDT 

DURECT Corp:Says it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.  Full Article

More From Around the Web


NASH: The next untapped pharma market gives investors many options

Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.